Monitor potential long-term adoption of the consensus guidance by German hospitals, which could benefit PICO7 sales, but no near-term catalyst is present. The filing is a routine clinical publication with no immediate trading implications.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 9 $30.40entry
- T+1 · 4mo ago +0.99%α +0.56% · $30.70
- T+5 · 4mo ago +3.32%α +3.45% · $31.41
- T+20 · 3mo ago −2.34%α −4.58% · $29.69
- T+60 · 7w ago −13.09%α −14.73% · $26.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Smith+Nephew announced the publication of new German consensus-based guidance recommending prophylactic single-use negative pressure wound therapy (sNPWT) for high-risk closed surgical incisions, supported by its PICO7 system. The press release is a clinical and health economics publication with no financial results or guidance, despite being filed under Item 2.02 (Earnings).
Key Facts
- New German consensus guidance published in Die Chirurgie recommends prophylactic sNPWT for high-risk closed surgical incisions.
- Guidance cites PICO7 system as a canister-free, portable NPWT device delivering -80 mmHg for up to 7 days.
- Referenced studies show sNPWT reduces length of stay (18 vs. 9 days), staff workload (687.5 vs. 376 minutes), and material costs (€228 vs. €42).
- Smith+Nephew generated $6.2 billion in annual sales in 2025 (from 'About' section, not current quarter).
- No earnings results, EPS, revenue, or guidance are provided in this filing.
Financial Impact
No material financial impact from this clinical publication. The press release is not an earnings report.
Risk Factors
- No material risks identified from this filing; the consensus guidance is non-binding and adoption timelines are uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3324546 |
Track record
42 reports on SNN
6 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +8.02% at T+20 after the Jun 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 1/10 Entry $31.00 Now $30.97 −0.10% settles Nov 19
- Nov 4, 202612d ago 6-K Bearish 6/10 No price data
- Nov 4, 202612d ago 6-K Bearish 6/10 Entry $32.46 to $31.04 Now $30.97 +4.59% ▲ +4.37% +3.46% vs SPY
- Nov 2, 202614d ago 6-K Neutral 4/10 Entry $30.24 to $31.05 Now $30.97 +2.41% ▲ +2.68% +2.60% vs SPY
- Oct 22, 202625d ago 6-K Neutral 2/10 Entry $30.88 to $30.22 Now $30.97 +0.29% ▼ −2.14% −2.84% vs SPY
- Oct 8, 20265w ago 6-K Neutral 2/10 Entry $26.96 to $29.09 Now $30.97 +14.87% ▲ +7.90% +8.18% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Oct 1, 20266w ago 6-K Neutral 2/10 Entry $26.58 to $26.96 Now $30.97 +16.52% ▲ +1.43% +0.13% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
- Sep 23, 20267w ago Press Release Neutral 3/10 Entry $26.82 to $26.96 Now $30.97 +15.47% ▲ +0.52% +1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers